Evaluate of hepatic function after chemotherapy with oxaliplatin through the indocianine green test

• Grant number: 20/02922-6
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2021
• End date: January 31, 2024
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Wellington Andraus
• Grantee: Wellington Andraus
• Host Institution: Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Leonardo Gomes da Fonseca ; Luiz Augusto Carneiro D'Albuquerque ; Paulo Herman

Abstract

Chemotherapy (CT) induces histological changes in the liver parenchyma that include steatosis, steatohepatitis (CASH) and sinusoidal obstruction syndrome (SOS), However, little is known about the evolutionary impact of chemotherapy on liver function. Numerous studies have attempted to establish a way to assess liver function in patients undergoing chemotherapy treatment. In this sense, indocyanine green (ICG), a synthetic tincture exclusively removed from the plasma by the liver and excreted in bile, appears as a toll to assess liver function in a less invasive way, through spectrophotometry. Objectives: Evaluate the liver function of patients with colorectal cancer (CRC) undergoing adjuvant chemotherapy based on Oxaliplatin through hepatic ICG clearance and correlating with the type of agent and the scheme used, as well as the treatment time for each of these agents. Materials and methods: Prospective and analytical work, based on the follow-up of patients with CRC submitted to adjuvant CT, at the Cancer Institute of the State of São Paulo (ICESP). It is estimated that forty-three patients will be included, who will receive an intravenous injection of 0.25 mg/kg of ICG, dissolved in 5 ml of saline solution, before starting CT and every 2 months, until the end of it, as well as every 2 weeks post CT, for a period of 10 weeks. The LiMON® device (Pulsion Medical Systems, Munich, Germany), which assesses the elimination of ICG using its pulse spectrophotometry, will be used to measure its plasma clearance rate (TDP% / min) and its retention rate after 15min (R 15% / min) each time the VI is injected. The variables age, sex, body mass index, total bilirubin and fractions, albumin, transaminases, alkaline phosphatase, gamma-glutamyl transferase, prothrombin time, platelets, creatinine will also be analyzed. (AU)